Law360 (September 9, 2019, 8:32 PM EDT) -- The government has delayed a hearing on the proposed sale of the flagship fentanyl spray that dragged Insys Therapeutics Inc. into bankruptcy, saying the disgraced drugmaker didn't give it enough time to make sure the deal complies with various laws and regulations.
The proposed sale of Insys' powerful Subsys spray to Wyoming-based BTcP Pharma was first announced in a regulatory notice filed Aug. 31 with the U.S. Securities and Exchange Commission, but on Monday the government said that just wasn't enough time to evaluate the deal ahead of a scheduled hearing on Wednesday, Sept. 11.
"Therefore, the United States respectfully requests...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!